[1. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.10.1200/JCO.2004.09.04614665611]Search in Google Scholar
[2. Arevalo Lobera S, Sagastibeltza Marinelarena N, Elejoste Echeberria I, Mele Olive M, Egana Otano L, Basterretxea Badiola L, et al. Fatal pneumonitis induced by oxaliplatin. Clin Transl Oncol 2008; 10: 764-7.10.1007/s12094-008-0285-719015075]Search in Google Scholar
[3. Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8.10.2478/v10019-009-0004-1]Search in Google Scholar
[4. Rebersek M, Boc M, Cerkovnik P, Benedik J, Hlebanja Z, Volk N, et al. Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis. Radiol Oncol 2011; 45: 285-91.10.2478/v10019-011-0039-y342375722933967]Search in Google Scholar
[5. Jung KH, Kil SY, Choi IK, Seo JH, Shin C, Kim YS, et al. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX). Int J Tuberc Lung Dis 2006; 10: 1181-2.]Search in Google Scholar
[6. Mundt P, Mochmann HC, Ebhardt H, Zeitz M, Duchmann R, Pauschinger M. Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer. Oncology 2007; 73: 270-2.10.1159/00012742518424892]Search in Google Scholar
[7. Park S, Jung JJ, Kim GB, Yoon HS, Ko SH, Ko JE, et al. Interstitial lung disease associated with combination chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin. Korean J Gastroenterol 2010; 55: 340-3.10.4166/kjg.2010.55.5.34020697195]Search in Google Scholar
[8. Trisolini R, Lazzari Agli L, Tassinari D, Rondelli D, Cancellieri A, Patelli M, et al. Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy. Eur Respir J 2001; 18: 243-5.10.1183/09031936.01.18010243]Search in Google Scholar
[9. Parambil JG, Myers JL, Aubry MC, Ryu JH. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy. Chest 2007; 132: 50-7.10.1378/chest.07-010417475632]Search in Google Scholar
[10. Goldstein D, Mitchell P, Michael M, Beale P, Friedlander M, Zalcberg J, et al. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. Br J Cancer 2005; 92: 832-7.10.1038/sj.bjc.6602426236191915756253]Search in Google Scholar
[11. Lami L, Areces F, Lence JJ, Arbesu MA. FOLFOX-4 Regimen as a first-line therapy for cuban patients with metastatic colorectal cancer. MEDICC Rev 2009; 11: 34-8.10.37757/MR2009V11.N3.821483305]Search in Google Scholar
[12. Nagata N, Kondo K, Kato T, Shibata Y, Okuyama Y, Ikenaga M, et al. Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study. Hepatogastroenterology 2009; 56: 1346-53.]Search in Google Scholar
[13. Lim JH, Kim H, Choi WG, Lee MH. Interstitial lung disease associated with FOLFOX chemotherapy. J Cancer Res Ther 2010; 6: 546-8.10.4103/0973-1482.7706621358098]Search in Google Scholar
[14. Muneoka K, Shirai Y, Sasaki M, Wakai T, Sakata J, Hatakeyama K. Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX). Int J Clin Oncol 2009; 14: 457-9.10.1007/s10147-008-0863-219856057]Search in Google Scholar
[15. Pena Alvarez C, Suh Oh HJ, Saenz de Miera Rodriguez A, Garcia Arroyo FR, Covela Rua M, Salgado Boquete L, et al. Interstitial lung disease associated with oxaliplatin: description of two cases. Clin Transl Oncol 2009; 11: 332-3.10.1007/s12094-009-0364-419451069]Search in Google Scholar
[16. Dahlqvist C, Fremault A, Carrasco J, Colinet B. Obliterative bronchiolitis with organising pneumonia following FOLFOX 4 chemotherapy. Rev Mal Respir 2010; 27: 84-7.10.1016/j.rmr.2009.06.00120146958]Search in Google Scholar
[17. Shimura T, Fuse N, Yoshino T, Minashi K, Tahara M, Doi T, et al. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Ann Oncol 2011; 21: 2005-10.10.1093/annonc/mdq06120305036]Search in Google Scholar
[18. Velenik V. Post-treatment surveillance in colorectal cancer. Radiol Oncol 2010; 44: 135-41.10.2478/v10019-010-0018-8342369922933905]Search in Google Scholar